LT3452053T - Apatinių šlapimo takų urotelinio vėžio gydymo būdas - Google Patents

Apatinių šlapimo takų urotelinio vėžio gydymo būdas

Info

Publication number
LT3452053T
LT3452053T LTEPPCT/US2017/031445T LTUS2017031445T LT3452053T LT 3452053 T LT3452053 T LT 3452053T LT US2017031445 T LTUS2017031445 T LT US2017031445T LT 3452053 T LT3452053 T LT 3452053T
Authority
LT
Lithuania
Prior art keywords
urothelial cancer
treating lower
lower tract
tract urothelial
treating
Prior art date
Application number
LTEPPCT/US2017/031445T
Other languages
English (en)
Inventor
Dennis GIESING
Christopher CUTIE
Purnanand SARMA
Cheryl Larrivee-Elkins
Christopher SEARCY
Vikas Agarwal
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of LT3452053T publication Critical patent/LT3452053T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/US2017/031445T 2016-05-06 2017-05-05 Apatinių šlapimo takų urotelinio vėžio gydymo būdas LT3452053T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (1)

Publication Number Publication Date
LT3452053T true LT3452053T (lt) 2023-02-10

Family

ID=60203435

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/031445T LT3452053T (lt) 2016-05-06 2017-05-05 Apatinių šlapimo takų urotelinio vėžio gydymo būdas

Country Status (22)

Country Link
US (1) US20190388338A1 (lt)
EP (2) EP3452053B1 (lt)
JP (3) JP2019514970A (lt)
KR (2) KR20220123317A (lt)
CN (1) CN109475571A (lt)
AU (1) AU2017261371B2 (lt)
BR (1) BR112018072551A2 (lt)
CA (1) CA3023274A1 (lt)
ES (1) ES2940227T3 (lt)
FI (1) FI3452053T3 (lt)
HR (1) HRP20221544T1 (lt)
HU (1) HUE060965T2 (lt)
IL (2) IL262746B (lt)
LT (1) LT3452053T (lt)
MX (2) MX2018013432A (lt)
PL (1) PL3452053T3 (lt)
PT (1) PT3452053T (lt)
RS (1) RS64032B1 (lt)
RU (2) RU2022100624A (lt)
SG (2) SG10201913416PA (lt)
SI (1) SI3452053T1 (lt)
WO (1) WO2017193098A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US10857173B2 (en) * 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
US10792297B2 (en) 2017-11-08 2020-10-06 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
SG177362A1 (en) 2009-06-26 2012-02-28 Taris Biomedical Inc Solid drug tablets for implantable drug delivery devices
HUE053888T2 (hu) 2009-12-17 2021-07-28 Taris Biomedical Llc Intravezikálisan tolerálható beültethetõ eszköz
NZ708506A (en) * 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
SI2600800T1 (sl) 2010-08-05 2021-03-31 Taris Biomedical Llc Naprava za dovajanje zdravila preko sečevodnega stenta in komplet
KR20140048086A (ko) 2011-02-04 2014-04-23 타리스 바이오메디컬 인코포레이티드 저 용해성 약물의 제어 방출을 위한 이식가능한 디바이스
CA2868431A1 (en) * 2012-03-29 2013-10-03 Altor Bioscience Corporation Methods for treating neoplasia
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX365688B (es) * 2012-08-31 2019-06-11 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
WO2014138214A1 (en) 2013-03-05 2014-09-12 Taris Biomedical, Inc. Drug delivery devices and methods for controlled drug release through device orifice
NZ711416A (en) 2013-03-15 2018-02-23 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
MX2015012367A (es) 2013-03-15 2016-05-31 Taris Biomedical Llc Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
PL3113782T3 (pl) * 2014-03-06 2023-01-23 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza moczowego gemcytabiną
WO2015200752A1 (en) 2014-06-26 2015-12-30 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods

Also Published As

Publication number Publication date
MX2018013432A (es) 2019-08-12
RU2764747C2 (ru) 2022-01-20
PL3452053T3 (pl) 2023-05-08
RU2018142908A3 (lt) 2020-08-31
KR102435709B1 (ko) 2022-08-25
AU2017261371A1 (en) 2018-12-13
CA3023274A1 (en) 2017-11-09
WO2017193098A1 (en) 2017-11-09
EP4209221A1 (en) 2023-07-12
RS64032B1 (sr) 2023-04-28
FI3452053T3 (fi) 2023-04-12
EP3452053A1 (en) 2019-03-13
RU2022100624A (ru) 2022-02-09
KR20190005204A (ko) 2019-01-15
SG10201913416PA (en) 2020-03-30
RU2018142908A (ru) 2020-06-08
SG11201809838VA (en) 2018-12-28
MX2021013461A (es) 2021-12-10
PT3452053T (pt) 2023-03-03
US20190388338A1 (en) 2019-12-26
IL295592A (en) 2022-10-01
HUE060965T2 (hu) 2023-04-28
SI3452053T1 (sl) 2023-03-31
ES2940227T3 (es) 2023-05-04
IL262746A (en) 2018-12-31
CN109475571A (zh) 2019-03-15
IL262746B (en) 2022-09-01
JP2019514970A (ja) 2019-06-06
KR20220123317A (ko) 2022-09-06
JP2024028881A (ja) 2024-03-05
EP3452053B1 (en) 2022-12-14
AU2017261371B2 (en) 2023-07-06
BR112018072551A2 (pt) 2019-02-19
HRP20221544T1 (hr) 2023-02-17
JP2022009327A (ja) 2022-01-14
EP3452053A4 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
HK1258098A1 (zh) 治療癌症的方法
HK1251409A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
IL263925A (en) Methods of treating ovarian cancer
IL275663A (en) Cancer treatment methods
HK1252272A1 (zh) 使用抗ox40抗體治療癌症的方法
IL262005A (en) Methods of treating cancer in children
SG11201607130RA (en) Combination method for treatment of cancer
IL262342A (en) Cancer treatment methods
ZA201808258B (en) Methods of treating pancreatic cancer
HK1251927A1 (zh) 用於治療癌症的新穎生物標記和方法
ZA201908539B (en) Method of treatment of cancer
IL263835A (en) Exosome-guided treatment of cancer
IL262746A (en) A method for treating urothelial cancer in the lower system
SG11202005163PA (en) Methods of treating cancer
GB201717945D0 (en) Method for treatment of cancer
IL269123A (en) Methods of treating cancer
GB201510197D0 (en) Method of treating ovarian cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer